These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1217 related articles for article (PubMed ID: 17687129)

  • 21. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A.
    Nagae C; Yamashita A; Ashikaga T; Mori M; Akita M; Kitsukawa K; Yamazaki S; Yoshikawa K; Yamamoto H; Taki M
    Int J Hematol; 2016 Aug; 104(2):208-15. PubMed ID: 27125646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of haemophilic arthropathy in children: a Lithuanian--Danish comparative study.
    Saulyte Trakymiene S; Clausen N; Poulsen LH; Ingerslev J; Rageliene L
    Haemophilia; 2013 Mar; 19(2):212-8. PubMed ID: 23167920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).
    Gringeri A; Lundin B; von Mackensen S; Mantovani L; Mannucci PM;
    J Thromb Haemost; 2011 Apr; 9(4):700-10. PubMed ID: 21255253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
    Schlenkrich S; Schubert C
    Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.
    Warren BB; Thornhill D; Stein J; Fadell M; Ingram JD; Funk S; Norton KL; Lane HD; Bennett CM; Dunn A; Recht M; Shapiro A; Manco-Johnson MJ
    Blood Adv; 2020 Jun; 4(11):2451-2459. PubMed ID: 32492157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylaxis and continuous infusion for hemophilia: can we afford it?
    Aledort LM; Bohn RL
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country.
    Verma SP; Dutta TK; Mahadevan S; Nalini P; Basu D; Biswal N; Ramesh A; Charles D; Vinod KV; Harichandra Kumar KT
    Haemophilia; 2016 May; 22(3):342-8. PubMed ID: 26987935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with prophylaxis in Sweden.
    Nilsson IM
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
    [No Abstract]   [Full Text] [Related]  

  • 33. [Analysis of individualized primary prophylactic treatment of 19 cases of children with severe hemophilia A].
    Liu GQ; Tang L; Wu XY; Zhen YZ; Li G; Chen ZP; Wang Y; Zhang NN; Zhang JS; Yu GX; Wu RH
    Zhonghua Er Ke Za Zhi; 2016 Dec; 54(12):923-926. PubMed ID: 27938593
    [No Abstract]   [Full Text] [Related]  

  • 34. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
    N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis.
    Smith PS; Teutsch SM; Shaffer PA; Rolka H; Evatt B
    J Pediatr; 1996 Sep; 129(3):424-31. PubMed ID: 8804333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue-inhibitors of metalloproteinase-1 and vascular-endothelial growth-factor in severe haemophilia A children on low dose prophylactic recombinant factor VIII: Relation to subclinical arthropathy.
    Andrawes NG; Saker HM; Salah El-Din NY; Abd Elhakim Hussain M
    Haemophilia; 2020 Jul; 26(4):607-614. PubMed ID: 32445517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children.
    Chozie NA; Primacakti F; Gatot D; Setiabudhy RD; Tulaar ABM; Prasetyo M
    Haemophilia; 2019 Jul; 25(4):633-639. PubMed ID: 31044491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience with prophylaxis in Germany.
    Schramm W
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):12-5. PubMed ID: 8367737
    [No Abstract]   [Full Text] [Related]  

  • 39. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.
    Berntorp E
    Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS).
    Yao W; Ai D; Zhang Q; Li X; Zhou M; Zhang N; Yang S; Chen Z; Zhen Y; Luke KH; Wu R
    Thromb Res; 2024 Sep; 241():109110. PubMed ID: 39116483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.